A PYMNTS Company

US: Arrowhead, Janssen sign US$3.7b license and collaboration deal

By  |  October 11, 2018

Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    ARO-HBV is the third generation subcutaneously administered RNA interference (RNAi) therapy of Arrowhead being developed as a potential curative therapy for patients with chronic HBV infection.

    The companies have also signed a research collaboration and option agreement for up to three additional RNAi therapeutics against new targets.

    “An important objective within Janssen is to develop highly effective combination products that cure people living with chronic hepatitis B infections,” said Mathai Mammen, Global Head of Janssen Research & Development. “Working with the talented Arrowhead team and their RNAi therapy candidate adds to the strength of our hepatitis B portfolio and substantially increases our confidence that we can achieve our objective.”

    The transactions are subject to clearance under the Hart-Scott-Rodino Act and expected to close in Q4 2018.

    Full Content: PR Newswire

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.